Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISC 2024 | What do we know about atrial cardiopathy & ESUS?

Aristeidis Katsanos, MD, McMaster University, Hamilton, Ontario, Canada, shares his thoughts on the ARCADIA trial, which assessed the superiority of anticoagulation versus antiplatelet therapy for prevention of recurrent stroke in patients with cryptogenic stroke and evidence of atrial cardiopathy. Evidence has suggested that ischemic stroke can arise from a thrombogenic atrial substrate even in the absence of atrial fibrillation. Despite this, apixaban did not significantly reduce recurrent stroke risk compared with aspirin. Dr Katsanos notes that refinement of atrial cardiopathy criteria may be necessary to see results. Ongoing subgroup analyses are likely to shed more light on this question. This interview took place during the International Stroke Conference 2024 in Phoenix, AZ.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.